Impairing TRPC6 activity in vitro in human glioma cells induced cell cycle arrest at the G2/M phase and, in vivo, reduced human xenograft growth in immunocompromised mice, while increasing the survival of the xenografted mice (Ding et al., 2010). Here, TRPC6 is linked to central nervous system cancer.